Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome

References

• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–2654.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–995.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.
   PubMed Web of Science ®Google Scholar
• Dinner S, Witteles W, Witteles R, et al. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol. 2013;161:367–372.
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31:4319–4324.
   PubMed Web of Science ®Google Scholar
• Dittus C, Uwumugambi N, Sun F, et al. The Effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:1729–1732.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Muchtar E, Kumar SK, et al. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leuk Lymphoma. 2017;58:308–315.
   PubMed Web of Science ®Google Scholar
• Paiva B, Vídriales M-B, Pérez JJ, et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood. 2011;117:3613–3616.
   PubMed Web of Science ®Google Scholar
• Paiva B, van Dongen JJM, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–3068.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Jevremovic D, Dispenzieri A, et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood. 2017;129:82–87.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317–2325.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–3757.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz M, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881–1887.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Schönland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420–3427.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–4549.
   PubMed Web of Science ®Google Scholar
• Delgado J, Pereira A, Villamor N, et al. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99:1410–1420.
   PubMed Web of Science ®Google Scholar
• Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325–2332.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116:5126–5129.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kyle RA, Greipp PR. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood. 1989;74:1108–1111.
   PubMed Web of Science ®Google Scholar
• Perfetti V, Colli Vignarelli M, Anesi E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica. 1999;84:218–221.
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Milani P, Basset M, Russo F, et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130:625–631.
   PubMed Web of Science ®Google Scholar
• Dittrich T, Bochtler T, Kimmich C, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130:632–642.
   PubMed Web of Science ®Google Scholar
• Sidana S, Tandon N, Dispenzieri A, et al. Clinical presentation and outcome in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2017. DOI: 10.1038/leu.2017.286. [Epub ahead of print].
   Web of Science ®Google Scholar
• Rodríguez-Lobato LG, Fernández de Larrea C, Cibeira MT, et al. Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. Amyloid. 2017;24:245–252.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma workshop consensus panel 2. Blood. 2011;117:4696–4700.
   PubMed Web of Science ®Google Scholar
• Bochtler T, Hegenbart U, Kunz C, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128:594–602.
   PubMed Web of Science ®Google Scholar
• Hwa YL, Kumar SK, Gertz MA, et al. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol. 2016;91:984–988.
   PubMed Web of Science ®Google Scholar
• Desikan KR, Dhodapkar MV, Hough A, et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma. 1997;27:315–319.
   PubMed Web of Science ®Google Scholar
• Siragusa S, Morice W, Gertz MA, et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol. 2011;90:101–106.
   PubMed Web of Science ®Google Scholar
• Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010;85:232–238.
   PubMed Web of Science ®Google Scholar